SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Third Quarter 2009 Financial Results - Conference call scheduled Monday, November 16, 2009 at 9:00 a.m. ET - BEIJING, Nov. 15 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2009. Financial Highlights · Sales for the] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T03:59:18+00:00 November 18th, 2009|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: Sinovac Reports Unaudited Third Quarter 2009 Financial Results

[Sinovac Reports Unaudited Third Quarter 2009 Financial Results - Conference call scheduled Monday, November 16, 2009 at 9:00 a.m. ET - BEIJING, Nov. 15 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2009. Financial Highlights · Sales for the] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F o o o SINOVAC BIOTECH LTD.]

By | 2016-03-24T04:00:34+00:00 November 18th, 2009|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number PART I. FINANCIAL INFORMATION] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Bennet P. Tchaikovsky, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v166458_ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v166458_ex32-2.htm]

By | 2016-03-01T06:57:32+00:00 November 16th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number

[SKYSTAR BIO-PHARMACEUTICAL COMPANY FORM 10-Q INDEX Page Number PART I. FINANCIAL INFORMATION] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Bennet P. Tchaikovsky, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer EX-32.1 5 v166458_ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v166458_ex32-2.htm]

By | 2016-03-01T06:58:15+00:00 November 16th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[Skystar Bio-Pharmaceutical Company Announces Third Quarter 2009 Financial Results Company Reports Record Quarterly Revenue of $12.78 Million and Adjusted Net Income of $4.25 Million; and Adjusted EPS of $0.61 Per Share XI'AN, CHINA – November 16, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) THIRD QUARTER 2009 HIGHLIGHTS § Revenue increased 27.1% period over period to $12.78 million. § Gross margin]

By | 2016-03-01T06:59:07+00:00 November 16th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Skystar Bio-Pharmaceutical Company Announces Third Quarter 2009 Financial

[Skystar Bio-Pharmaceutical Company Announces Third Quarter 2009 Financial Results Company Reports Record Quarterly Revenue of $12.78 Million and Adjusted Net Income of $4.25 Million; and Adjusted EPS of $0.61 Per Share XI'AN, CHINA – November 16, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) THIRD QUARTER 2009 HIGHLIGHTS § Revenue increased 27.1% period over period to $12.78 million. § Gross margin]

By | 2016-03-01T06:59:42+00:00 November 16th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Read More
Skip to toolbar